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Enhanced lymphokine-activated killer cell activity by an
immunomodulator, Roquinimex
F Vaz, MRG Silva and JL Ascensao
Portuguese Institute ofOncology, Lisbon, Portugal; University ofNevada School ofMedicine, Nevada, USA; VA Medical Center,
Reno, Nevada, USA
Summary Roquinimex (Roq) is an immunomodulator known to stimulate cellular immune responses. It is
currently used for immunotherapy after bone marrow transplantation (BMT). One of the major features of
this compound is an enhancement of natural killer (NK) cell activity and numbers. We studied the in vitro
effect of Roq on human peripheral blood NK and adherent lymphokine-activated killer cell (ALAK) activities.
In cultures supplemented with recombinant interleukin 2 (rIL-2) (1000 U ml-') and Roq a significant increase
in NK and LAK function was observed without a parallel increase in cell numbers. We also examined the
generation of NK cells from human bone marrow (BM) immature progenitors, obtained by purging with
4-hydroperoxycyclophosphamide (4HC). NK cell numbers and activity were both increased when cultures with
rIL-2 (10 U ml- ') were supplemented with Roq. These results confirm findings obtained in vivo and in vitro in
the murine system and suggest that Roq is an active agent on these lymphoid populations. These properties
and good tolerability make Roq an attractive tool for immunotherapy.
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Roquinimex (Roq) (quinoline-3-carboxamide) is a compound
that has been shown to have immunomodulator and anti-
tumour activity in various animals and human model systems
and is well tolerated. Roq was found to have therapeutic
effects in primary tumours and metastasis (Kalland et al.,
1985a; Kalland, 1986), and its impact following autologous
bone marrow transplantation (ABMT) for acute myelo-
genous leukaemia (AML) (Simonsson et al., 1992; Rowe et
al., 1993a) and chronic myelogenous leukaemia (CML)
(Rowe et al., 1993b) is currently under investigation. Its
immunomodulator properties have also proven useful in the
amelioration of the autoimmune manifestations of murine
encephalomyelitis (Karussis et al., 1993a,b), collagen-induced
arthritis (Kleinau et al., 1989) and lupus-like disease (Tar-
kowski et al., 1986a,b) as well as in parasitic and viral
infections (Ilback et al., 1989).
One of the major features of Roq is an enhancement of
NK cell activity and numbers (Kalland et al., 1985b; Kal-
land, 1990; Bengtsson et al., 1992). NK cells are important
components of the immune system that exhibit non-MHC-
restricted cytolytic activity against tumours (Herberman et
al., 1979; Gorelik and Herberman, 1986; Felsher, 1990), virus
infected cells (Welsh, 1981) and tissue grafts (Lotzova et al.,
1979; Cuturi et al., 1989). Cancer patients with low NK cell
activity have been found to have an increased relapse rate
(Pizzolo et al., 1988) and their early recovery in the period
after BMT may be essential in the eradication of residual
tumour cells and defence against infection. Interleukin 2
(IL-2)-activated NK cells are LAK effectors. Adherent LAK
(ALAK) cells have been shown to have more potent cytolytic
activity than do unfractionated LAK cells (Melder et al.,
1988; Vujanovic et al., 1988; Verfaillie et al., 1989). Because
therapy with Roq is well tolerated and has few side-effects,
the results obtained so far.in the human and murine models
appear promising. The results obtained in in vivo murine
experiments showing activation of NK and LAK cell pro-
liferation and activity have not been confirmed in vitro in the
murine system and its mode of action has not been fully
investigated in humans.
In this report we describe the enhancement of human
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peripheral blood NK and LAK cell function in vitro by Roq.
In human bone marrow, NK cell numbers and function were
both increased in cultures containing this compound. We
suggest that Roq is active in vitro in stimulating NK and
LAK activity in mature peripheral blood cells; at the precur-
sor cell level Roq is capable of increasing NK cell numbers
and activity.
Materials and methods
Reagents
Roquinimex is a quinoline-3-carboxamide, its tradename is
Linomide (Pharmacia Lund, Sweden).
Production ofALAK cells
Peripheral blood was obtained from healthy donors after
informed consent was given. ALAK cells were produced as
previously described (Melder et al., 1988; Vujanovic et al.,
1988). Briefly, peripheral blood mononuclear cells (PBMNCs)
obtained by Ficoll Hypaque (Histopaque; Sigma Diagnostics,
St Louis, MO, USA) depleted of monocytes by plastic
adherence were suspended in culture medium containing
1000 U ml-' rIL-2 (a gift from B Mukherji) in horizontal
T25 flasks (Costar, Cambridge, MA, USA) at a concentra-
tion of 1.5-2 x 106, for 24 h, at 37C in 5% carbon dioxide
in a humidified atmosphere. Culture medium used for rIL-2
incubations consisted of Iscoves's modified Dulbecco medium
(IMDM) (Gibco, Grand Island, NY, USA) supplemented
with 10% human heat-inactivated AB male serum (Lot no.
93108, NABI, Miami, FL, USA) plus 1% of penicillin G
sodium (1000OUml-')-streptomycin sulphate (10000 g
ml-') (Pen-Strep; Gibco). After 24 h incubation, the super-
natant was decanted and all cells not firmly attached to the
plastic were removed by washing three times with IMDM.
The plastic adherent (ALAK) cells were then fed with fresh
media supplemented with rIL-2 (1000 U ml-'), Roq (25 lig
ml-' or 50tLg ml-') or combinations for up to 14 days. One
additional control included cells grown in fresh media with-
out factors. Cultures were fed twice weekly by substituting
50% of culture media with fresh media with factors. At
termination of culture cells were recovered by washing the
flasks with cold IMDM or with phosphate-buffered saline
(PBS) containing 0.01 M EDTA.LAK cell activity by Roquinimex
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Preparation of bone marrowt stromlas
Bone marrow was harvested from healthy donors after in-
formed consent was obtained. The mononuclear cells were
isolated by centrifugation on a Ficoll-Hypaque density
gradient and washed twice in IMDM. Approximately
35-40 x 106 cells were cultured in 75 cm2 tissue culture flasks
in 15 ml of IMDM supplemented with 10% equine serum
(Hyclone Laboratories, Logan, UT, USA), 2 x 10-6 M hyd-
rocortisone (Sigma) and 1% Pen-Strep for 4 weeks at 37°C in
5% carbon dioxide humidified air atmosphere. Medium was
changed twice a week. When a confluent stromal layer was
established, cells were trypsinised using Trypsin-EDTA
(Sigma), irradiated at 1500 cGy with a cobalt source and
transferred to 25 cm2 tissue culture flasks precoated with
gelatin (Gibco). 4HC-treated and untreated allogeneic bone
marrow mononuclear cells (BMMNCs) were then added and
cultured over these confluent stromas.
4HC treatment of BMMNC
Bone marrow from three healthy donors was harvested and
BMMNCs obtained as described (Cardoso et al., 1992).
Briefly, aliquots of BMMNCs in IMDM supplemented with
20% fetal bovine serum (FBS) at a concentration of
2 x 107ml-1 were incubated with or without 60 igml-' of
4HC (Scios-Nova, Baltimore, MD, USA) for 30 min at 37°C
with constant gentle agitation; 4HC was prepared just before
each experiment because it is unstable in solution. The reac-
tion with 4HC was stopped by the addition of chilled IMDM
supplemented with 10% FBS, the cells washed in cold sup-
plemented medium and centrifuged for 10 min at 200g.
4HC-treated and untreated BMMNCs were cultured over the
irradiated, allogeneic BM stromal layers prepared as des-
cribed above, in 4 ml of IMDM supplemented with 10%
heat-inactivated human AB serum and 1% Pen-Strep at a
concentration of 1 x 106 ml - for non-4HC-treated and
4-5 x 106ml-' for 4HC-treated cells. These cultures were
supplemented with rIL-2 (10 U ml-') or rIL-2 (10 U ml-')
plus Roq 50 tLg ml '. All the cultures were maintained at
37TC in 5% carbon dioxide humidified air for 28 days and
the media (with or without factors) changed twice a week.
The cultures were harvested after 28 days by careful but
vigorous aspiration and washing of the cells in suspension,
and phenotypic and functional analysis were performed on
this population.
Target cells
The NK-sensitive erythroleukaemia cell line K562 and the
NK resistant lymphoblast-like cell line Raji (ATCC, Rock-
ville, MD, USA) were used as targets to assess NK and LAK
activity. Before each assay, viability was determined by
trypan blue exclusion and ranged from 85% to 98%.
Cytotoxicity assa.ys
ALAK cells obtained in our cultures were tested for cytotox-
icity against the NK-sensitive K562 cell line and the NK-
resistant Raji cell line in a standard 4 h chromium-51 release
assay (Cardoso et al., 1992). Approximately 1-2 x 106 target
cells were washed and incubated for 90 min at 37°C with
sodium chromate (Dupont, Boston, MA, USA) at 0.1 mCi
10-6 target cells. The cells were then washed five times in
IMDM supplemented with 5% FBS and counted. Effector
cells harvested from the cultures on the day of analysis were
washed, counted, their viability assayed by trypan blue ex-
clusion and seeded in V-shaped microwell plates (Nunc,
Naperville, IL, USA) at effector-target ratios that ranged
from 10: 1 to 1.25:1. The plates were then centrifuged at
120g for 3 min and incubated for 4 h at 37TC in a 5%
carbon dioxide humidified air atmosphere. After this period
the plates were centrifuged at 200 g and 0.1 ml of the super-
natants was removed from each well and withdrawn into
aliquots of 1 ml of liquid scintillation cocktail (Ready safe;
Beckman Instruments, Fullerton, CA, USA). Radioactivity
was measured in a scintillation counter (Packard Instru-
ments, Downers Grove, IL, USA). All determinations were
done in triplicate and percentage lysis was determined using
the following equation:
Specific lysis (%) =
Experimental mean c.p.m. - spontaneous release mean c.p.m.
Total release mean c.p.m. - spontaneous release mean c.p.m.
x 100
Maximal chromium-5I release was determine by adding
0.1 ml of 1% sodium dodecyl sulphate solution (Sigma) to
labelled target cells. Spontaneous chromium-51 release, as
determined by adding 0.1 ml of supplemented medium to
target cells, averaged 20%.
PhenotYpe
Cell surface antigens were determined by direct staining of
the cells with monoclonal antibodies (Becton-Dickinson, San
Jose, CA, USA) fluorescein (FITC)-conjugated anti-CD45
(Hle-1) CD3 (Leu-4) and the phycoerythrin (PE)-conjugated
MAb CD14 (Leu M3) and CD56 (Leu-19). Appropriate
controls included FITC- and PE-conjugated irrelevant MAbs
(Simultest: Becton Dickinson). After twice washing the cells
in IMDM supplemented with 5% FBS they were labelled
with a saturating concentration of MAb for 15 min at room
temperature in the dark. The cells were then washed twice in
PBS 0.5% sodium azide and fixed with 1% parafor-
maldehyde. Dual-colour analyses were performed with a
FACScan flow cytometer (Becton-Dickinson). At least
10 000 cells per aliquot were analysed and gated on the
presumptive lymphocyte region as defined by forward and
side scatter. Upon analysis, quadrants were positioned in
order to allow at least 99% of the control, isotypic-labelled
population to remain in the negative quadrant. NK cells were
phenotypically defined as CD3 - CD56+.
Statistical analsis
The results were expressed as mean ± s.e.m. of data obtained
in 6-9 experiments for peripheral blood cultures and two
experiments for bone marrow cultures. Statistical analysis
was done using the binomial test. Statistical significance was
defined by P<0.05.
Results
Proliferation ofALAK cellsfrom peripheral blood
The cells recovered at the end of culture were not derived
from the total number of cells plated at day 0, but from the
adherent fraction retained after decanting the non-adherent
population at 24 h of culture. Therefore, the index of cell
proliferation in ALAK cultures was calculated as the ratio
between the number of cells in each culture and the control
cultures (Figure 1). Cultures only supplemented with rIL-2
had the highest proliferation rate (6.0 ± 1.1) as compared
with the control. By comparison, when Roq was added to
rIL-2 the difference in cell expansion was not statistically
significant (P = 0.3 for rIL-2 plus Roq 50 jig ml-' and
P=0.1 for rIL-2 and Roq 25 1ig ml-'). Roq by itself was not
able to stimulate cell proliferation (1.3 ± 1.8 at a concentra-
tion of 25 jig ml- and 0.8 ± 6.0 at 50 ig ml- ').
Functional anal ysis
ALAK cultures In six experiments the cytotoxicity of
ALAK cells was tested both aginst K562 and Raji targets.
The cells grown in rIL-2 and Roq (25 glg ml-') had
significantly higher cytotoxic activity against the Raji cell line
than the cells grown in the presence of rIL-2 alone (Table I)
(P = 0.03). Figure 2 shows the results of one representative
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experiment. However. rIL-2 Roq 50 pg ml-' did not increase
LAK activitv (P = 0.3) as compared with rIL-2 alone. Roq
bx itself did not induce LAK actixix as reflected in the
coimiparison ot cultures without added factors and the ones
with Roq only (P = 0.3 for Roq 25pgrgml and P = 0.8 for
Roq 50 pg ml '). In only two of six experiments the addition
ot 50 pg ml Roq to IL-2 cultures increased the percentage
INsis of Raji targets as compared with rIL-2 alone (in one
experimiienit the increase was 32.8 at an E T ratio of 5:1 and
in the other this increase was at the same E T ratio).
NK actixitv as defined by lysis of K562 targets was
siliticantl\ enhanced by Roq (25 ' iml-) in cultures
already supplemiiented xwith rIL-2 (P = 0.01) (Table 11). The
rIL-2 + Roq 50 jig ml-' cultures were not signiticantlx
different trom the IL-2-actilated cells (P = 0.2). We did not
observe stimulaktion of NK activity by Roq alone as com-
pared with conitrol (P= 0.2) tor Roq 25 jig ml-' and P = 0.7
tor Roq 50 pg ml .
Bonti ;no(ii-rr-oa (tiultuires In cultures of 4HC' purged BMMNC
an increase in l_tic actix itx of NK targets was obserxved in
those supplemiienited x ith rlL-2 and Roq ( 14 ± 9.900 Isis at
an E T ratio ot 10:1) as compaIred with 5.7 6.1O% at the
samne E T raltio for cells grown onlv with rlL-2; at other
ratios, a simlar increase in Ixtic actixitv was observed (except
1.25:1 ) (Figure 3).
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AIL A cultures We harvested peripheral blood from nine
donors and analksed the ALAK cultures between 10 and 14
daxs of culture (Table II). A total of 26.7 ± 4.90O of the cells
cultured with Roq (25 fig nil -) alone were CD56 positive.
This was not difTerent from the expression of this phenotype
either in cultures with Roq -SOjg nil-' (25.2 ± 9.1 %) or in
cultures without added factors after the initial 24 h stimula-
tion with rIL-2 (27.3 + 2.1" ,O). CD56 expression in the cul-
tures with rIL-2 alone (nine experiments) was 46.3 ± 1.3°o1
and the addition of Roq at different concentrations did not
change the percentage of cells expressing the CD56
phenotype (43.0 2.0%O) in rlL-2 Roq (25 pg ml-') but
decre.ased to 36.0 ± 0.8°0o for rlL-2 Roq (S0 pg ml-'). T lym-
phocyte numbers, as defined by CD3 expression, were no
difTerent in cultures with or without Roq but without rIL-2;
in rIL-2-containing cultures Roq at either dose showed an
increase in CD3
+ cells (5.50o at 25 fig ml-' of Roq and 6.9%
in IL-' + Roq SO(pg ml - 1).
Botn0 ini(1ro1 oit, cturcP o)f 4-HC-purgedl BMMAINC Phenotypic
anallsis of 4HC-trealted and non-4HC-treated BMMNC over
allogeineic marrow stromas for 4 weeks with a low dose of
rlL-2 and Roq (50 ig nil-') rex ealed an increaLse in CD56 +
cell generation froiii purged bone mnirrow (17.5 ±5.5%o) as
conipared with rIL-2 alone (9.2 ± 4.80o). The addition of
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Figure I Cell proliferation in Al AK cultures. The proliferation
inidex was calculated as the ratio between the number ot cells in
each culture and control culture. Roq 25. Roq 25 'pg nil Roq
50) Roq 50 fig ml K: IL-2' rI -2 1000 U nil .; IL-2 + Roq 25'
rlI -2 10000 U nil and Roq 25 jig nil -; IL-2 + Roq 50, rl -2
1 )010 t nil a .and Roq 50 jg ml
5:01 2.5:1 1.25:1
E/T ratio
Figure 2 LAK aunction in IL-' cultures. Results of one
representatixe experiment are shown. A signiticaritlv (P<0.05)
higher cvtotoxicitx was observed ftr cells cultured with IL-2 and
Roq (25 pg ml ') (U) as compared with 11 - alone (*) 0,
rlL-2 (lOOO U nil 1) and Roq (5) pg ml--').
Table I Lysis ot Raji talrgets hb ALAK cultured cells"
F 17 rotio N\ot Roq 2i pg oml Roq 50 pgt mil IL-2 1000 U oil 11 -2 + Roq 2- pg mil IL-2 + Roq (50g ml`n!
1(:1 11.7+ A.4 1218±8.6 14.4 10.4 39.3 8.1 46.3 I".7 39.8+6.5
5: 1 7. 1 2.(0 5.6 + .2 + 7.7 30.8 + 7.5 38.7 10.5 34 1 + 6.7
5.:1 4.4 +22 5.67+ 3. 10.2 6.9 2.1 +7.2 32.7 +9.6 24.2±.5
1.25: 1 3.5 1.5 40. + 3.1 4.8 + 3.7 17.9 + 5.1 24.4 + 8.4 19.4 + 5.1
Values represent mealn + s iim oat six experimenits. Ftch experiment was done in triplicate, PP<0.0)5 is IL-2 1000 UT ml
Table 11 Lvsis ot K562 targets hb ALAK cultured cells"
E T ratio oNWI Roqj 2" pg oil Roqj '50 pgr mil I -2 1000 L oitl II -2 + Roq 25 tig itnl IL-2 + Roq 0 pgr mol'
1l):1 47.4± 11.7
5:1 44.5±13
25.:1 10.6 + 7.9
1.251 15.±+.0
47 51 ± 1(.2
30.0± 7.3
23.4 + 9.5
17.5 ± 9.5
39Q + I2. I
31.2± 13.1
25.7± 11.()
16.' ± 9 5
76.(0 ± 5 36
74.7 ± 8.6
67.31 ± 10.8
60.7+ 12.5
85.4 ± 4. 1
80.2 ± 4.0
81.0 + 8.9
67.9 ± 9.6
74.7 ± 6.0
7 1.1 ± 9.3
73.4 ± 8.4
66 ± 1 1.3
V'alues represenit me'an ± s.e.im. at six experinients. Each experiment was done in triplicate. PP<.005 is Il-2 1000 U mlT lLAK cell activity bY Roquinimex
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Table III Phenotype of cells in ALAK cultures
Surface
marker None Roq 25 ig ml- ' Roq 50 igml-' IL-2 1000 Uml-' IL-2 + Roq 25jg ml- IL-2 + Roq 50jg ml-I
CD56 27.3 ± 2.1 26.7 ± 4.9 25.0 ± 9.13 46.3 ± 1.3 43.0 2.0 36.0 ± 0.8
CD3 60.3 ± 1.8 59.5 ± 3.7 61.6 ± 2.5 46.6 ± 1.0 52.1 ± 2.2 53.5 ± 6.7
CD3/56 4.7 ± 4.5 5.7 ± 2.2 5.1 ± 2.9 10.9 ± 5.9 11.0 ± 3.3 12.2 ± 0.6
Results given as mean ± s.e. of the mean of nine experiments.
1.25:1 2.5:1 5:01 10:01
E/T ratio
Figure 3 Lysis of K562 targets in 4HC-treated bone marrow.
NK cells were generated from immature haematopoietic pro-
genitors (4HC-purged BM) in a standard long-term culture
system. An increase in NK function was observed in cultures with
low-dose IL-2 (10 U ml-') supplemented with Roq (50 fig ml-')
(m) as compared with IL-2 alone (0). The mean percentage lysis
of two experiments is shown.
Roq to rIL-2 cultures did not increase CD3 expression
(71.7 ± 8.2% for rIL-2/Roq vs 72.4 ± 13.7% for rIL-2 cul-
tures without Roq).
Discussion
Human NK and LAK cells are important in immune
defences against primary and metastatic tumours, viral infec-
tions, graft rejection and can stimulate or suppress
haemopoiesis through different mechanisms (Robertson and
Ritz, 1990).
Roq is a quinoline derivative that has immunomodulator
activity. The mode of action of Roq has been analysed
mainly in animal models of autoimmune and cancer diseases
where its relevance as a modulator of immunological (Kal-
land et al., 1985a; Kalland, 1986; Larsson et al., 1987) and
non-immune mechanisms (Ichikawa et al., 1992; Vukanovic
et al., 1993) has been shown. Its effect on NK function has
also been shown to be important in the control of metastasis
(Harning et al., 1989, 1990).
The mechanism of action of Roq and its effects on the
human systsem at the cellular level are still not well under-
stood. Studies in human recipients of autografts suggest that
Roq induces an increase in NK cell numbers and cytotoxicity
against both NK-sensitive and NK-resistant targets. Roq was
also capable of inducing the production of several cytokines
in these patients (Bengtsson et al., 1992; Simonsson et al.,
1992; Nilsson et al., 1993).
In the clinical setting, a standard dose of 0.2 mg kg-' Roq
will achieve an average blood level of 1.3 lag ml-'. We tested
doses from -100jig ml-' Roq in vitro, however it is likely
that some of the effects seen in vivo are due to production of
cytokines by accessory cells or to active metabolites which we
could not account for in our in vitro studies.
We first analysed the effects of Roq on an ALAK cell
population from human adult healthy donors. ALAK cells
were chosen because they represent a more homogeneous
LAK cell population and have been previously demonstrated
to possess stronger cytotoxic activity. When we analysed the
data from rIL-2 cultures supplemented with Roq, cytotoxic
activity, reflecting both NK and LAK function, was
significantly increased in rIL-2 cultures supplemented with
25 ig ml-' Roq. This did not correlate with a significant
increase of CD56-positive cells in these cultures. A lack of
correlation between the number of NK like cells and
cytotoxic effector function in Roq studies has already been
reported (Bengtsson et al., 1992). This could be due to the
activation of cytotoxic T cells. An increase in CD3 + cells was
observed in our system in the same type of culture in which
higher LAK and NK function was observed. On the other
hand, cells cultured with rIL-2/Roq 50tig ml-' had a similar
increase in CD3 + cells without a corresponding increase in
lytic activity.
We could not demonstrate, in our system, a stimulating
effect of Roq, by itself, on NK or ALAK function from
peripheral blood. These observations support those described
in the murine system where proliferation of NK and LAK
cells was observed when Roq was administered in vivo but
not in in vitro cultures of murine splenocytes (Kalland et al.,
1985b), thus suggesting that Roq acts on NK and LAK
precursors. Roq added to suboptimal concentrations of rIL-2
was shown to be effective in increasing NK cell generation
and cytotoxicity from murine bone marrow cultures in vitro
(Kalland, 1990). Based on these findings we decided to
evaluate the effect of Roq on NK BM precursors. We have
previously shown that NK cells can be derived from
primitive haemopoietic progenitors (Silva and Ascensao,
1995). 4HC purging of BMMNCs allows for maintenance of
only the most primitive haemopoietic progenitors destroying
populations of committed progenitors and mature cells
(Moore, 1991; Rowley et al., 1993), including active NK cells
and their late precursors in BM (Cardoso et al., 1992). Roq
was shown to increase the generation of CD56 + cells from
4HC-purged bone marrow when added to a suboptimal dose
of rIL-2. It also stimulated the activity of these cells. Roq
alone did not stimulate the development of NK cells in this
system (data not shown), confirming similar results in the
murine system.
Our findings indicate that Roq in combination with IL-2
enhances LAK and NK activity of human PBLs and
stimulates the generation of NK cells from immature
haematopoietic progenitors present in purged bone marrow,
in vitro. These observations confirm the role of Roq as a
stimulator of NK and ALAK activity in the human system.
With the exception of 4HC-purged marrow, Roq at
25 igmlm' had stimulatory activity on ALAK activity com-
pared with lack of such activity at 50fig ml-'. The different
effects of the different doses are compatible with, although
not proof of, the concept of a bell-shaped dose-response
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curve, which is a feature of quite a few immunomodulatory
agents. In vitro, Roq exerts its immune cellular effects both
on peripheral blood and at the bone marrow progenitor level
but with different results on NK cell proliferation and
cytolytic activity. These dual effects are similar to those
previously reported in the murine system and suggest that
different mechanisms exist for the regulation of mature and
progenitor NK cells. These properties and good tolerability
make Roq an attractive tool for immunotherapy.
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